26
Views
0
CrossRef citations to date
0
Altmetric
Review

Patent focus on antidiabetic agents: September 1999 - February 2000

Pages 787-801 | Published online: 25 Feb 2005
 

Abstract

This focus highlights the most relevant patent disclosures in the field of oral antidiabetic therapy for the period of September 1999 to February 2000. As diabetes is a multi-faceted disease of decreased insulin secretion, increased peripheral (muscle, fat and liver) insulin resistance and dysregulated hepatic glucose production, recent drug development activities have centred around insulin secretagogues, insulin sensitisers and inhibitors of hepatic glucose output. Of particular note recently, are agents which increase insulin sensitivity (PPARγ and RXR agonists), modulate the insulin signalling pathway (PTP-1B and GSK-3 inhibitors), decrease hepatic gluconeogenesis and/or glycogenolysis (G6Pase, F1,6BPase and GP inhibitors), modulate glucose metabolism (PDHK inhibitors) and increase insulin secretion (DPP IV inhibitors).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.